Adcetris for Hodgkin Lymphoma Resubmission – Details


( Last Updated : March 22, 2019)
Generic Name:
Brentuximab Vedotin
Project Status:
Complete
Therapeutic Area:
Hodgkin lymphoma (HL)
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris (Resubmission)
Project Line:
Reimbursement Review
Project Number:
PC0145-000
NOC Date:

Details


Strength:
50 mg
Tumour Type:
Lymphoma
Indications:
Hodgkin Lymphoma
Funding Request:
For the treatment of patients with HL after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates
Review Status:
Complete
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Funding Request:
For the treatment of patients with HL after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.